Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Express Scripts
Baxter
Colorcon
Johnson and Johnson

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR VEPESID

➤ Subscribe for complete access

« Back to Dashboard

505(b)(2) Clinical Trials for Vepesid

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Combination NCT05019716 ↗ Testing the Safety and Efficacy of the Addition of A New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Etoposide and Cisplatin) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma Not yet recruiting National Cancer Institute (NCI) Phase 1/Phase 2 2022-04-29 This phase I/II trial tests the safety, side effects, and best dose of a new combination of drugs, ZEN003694, cisplatin, and etoposide in treating patients with NUT carcinoma (phase I), and identifies whether this combination therapy works to shrink tumor in these patients (phase II). Another purpose of this study is to see whether there are any changes in patient's tumor or blood characteristics (e.g. genes, molecules, etc.) due to combination therapy. ZEN003694 inhibits the production of certain growth-promoting proteins and may prevent proliferation of tumor cells that use those proteins for their growth. Chemotherapy drugs, such as etoposide and cisplatin, work by stopping or slowing the growth of cancer cells. Combination therapy with ZEN003694, etoposide and cisplatin may be effective in treating patients with NUT carcinoma.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Vepesid

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00002524 ↗ Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed National Cancer Institute (NCI) Phase 2 1993-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002524 ↗ Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Completed M.D. Anderson Cancer Center Phase 2 1993-06-01 RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients with AIDS-related lymphoma.
NCT00002610 ↗ Chemotherapy With or Without Surgery, Radiation Therapy, or Stem Cell Transplantation in Treating Young Patients With Kidney Tumors Completed National Cancer Institute (NCI) Phase 3 1996-01-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. It is not yet known which therapy regimen is most effective for treating patients with kidney tumors. PURPOSE: Phase III trial to compare the effectiveness of chemotherapy with or without radiation therapy, surgery, and/or peripheral stem cell or bone marrow transplantation in treating young patients with kidney tumors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vepesid

Condition Name

Condition Name for Vepesid
Intervention Trials
Lymphoma 27
Leukemia 12
Recurrent Diffuse Large B-Cell Lymphoma 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vepesid
Intervention Trials
Lymphoma 83
Leukemia 47
Lymphoma, Non-Hodgkin 36
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vepesid

Trials by Country

Trials by Country for Vepesid
Location Trials
Canada 353
United States 3,065
Australia 144
New Zealand 44
Puerto Rico 37
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vepesid
Location Trials
Texas 110
California 104
New York 97
Missouri 86
Washington 84
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vepesid

Clinical Trial Phase

Clinical Trial Phase for Vepesid
Clinical Trial Phase Trials
Phase 3 46
Phase 2/Phase 3 5
Phase 2 91
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vepesid
Clinical Trial Phase Trials
Completed 93
Recruiting 47
Active, not recruiting 40
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vepesid

Sponsor Name

Sponsor Name for Vepesid
Sponsor Trials
National Cancer Institute (NCI) 153
Children's Oncology Group 47
M.D. Anderson Cancer Center 34
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vepesid
Sponsor Trials
Other 206
NIH 157
Industry 47
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Boehringer Ingelheim
Dow
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.